What key details about malcolm a. s. moore can be extracted from the following bio? Bio: malcolm a. s. moore , d.phil . -lrb- born january 18 , 1944 -rrb- is the enid a. haupt chair of cell biology at the memorial sloan-kettering cancer center . dr. moore is a noted oncologist and hematologist primarily known for being the principal investigator in the development of filgrastim , marketed by amgen under the brand name of neupogen and neulasta . over 3 million patients world-wide , mostly with cancer , have been treated with neupogen . g-csf mobilizes stem cells from the bone marrow into the circulation and subsequent peripheral blood leukapheresis produces sufficient stem cells for both autologous or allogeneic transplantation , reducing the need to obtain large volumes of bone marrow . such stem cell transplants give a faster recovery of white blood cells , platelets and red cells than seen with conventional bone marrow transplantation . g-csf stem cell transplants are used in treatment of leukemia , lymphoma and multiple myeloma resulting in prolonged remission and , in some cases , cure . he is a member of various national and international societies and is on the editorial boards of a number of journals . he has served or chaired committees of governmental and professional organizations .
- prizes is hope funds award of excellence in basic research .- work institutions is memorial sloan-kettering cancer center- field is oncology/hematology- birth date is 18 january 1944- name is malcolm a. s. moore- nationality is british- alma mater is oxford university